Kaituo Pharmaceutical - B: The safety trial of KT-939 in 119 people for 28 weeks showed no adverse reactions. The registration application has been initiated.

Expansion Pharmaceutical-B Announcement, the company's previously disclosed KT-939 human long-term safety trial was completed with all participants enrolled by September 2025. This voluntary announcement shows that the mid-term results of a total of 119 participants who used KT-939 continuously for 28 weeks showed no adverse skin reactions, demonstrating good safety. In addition, the company has recently started to submit the registration application materials for KT-939 cosmetic new raw materials to the National Medical Products Administration's subordinate China Inspection Institute, and will steadily progress in accordance with the guidance.